Top 10 products in the tens of billions of ophthalmic drugs market

Medicine Network June 2nd, following the introduction of heavy gold ophthalmology new drugs, Hengrui domestic first reported production of "net red" eye drops once again aroused market attentionIn recent years, the domestic ophthalmic drug market continues to grow, domestic pharmaceutical companies in this area of concern is also increasingAccording to minet data, china's public medical institutions in 2019 end-of-eye drug sales of 10,931 million yuan, an increase of 14.83 percent year-on-yearProduct TOP10, 3 productsales of more than 1 billion products, Compaxip sales growth rate leading; Since 2020, the domestic market a total of 5 eye drug products were approved for listing, Yangzijiang took the company's second ophthalmic drugXingqi eye medicine, which was popular in the capital market in 2019, has not been approved so far in 2020, and five product listing applications are in the review$160,
million after the introduction of new ophthalmology drugs, Hengrui sprint "net red" eye drop sequine first imitationrecently, CDE official website shows that Hengruimedicineto copy 4 categories of declaration of his fluoroproprosyl eye drops (receiving number CYHS2000022) listing application to be included in the priority review, included as a "clinically urgent need, market shortage ofdrug registrationapplication." He fluoroproproproproproprosin is a prostaglandin analogue, is a selective FP prostaglandin receptor agonist, can increase the amount of water flow through the grape membrane scloraic membrane to reduce the intra-eye pressure, used to reduce open-angle glaucoma and high eye pressure patients with elevated eye pressureHis fluoroproproszolat eye drops, developed by Japan's Saitama Pharmaceuticals, are a "net red" product that was launched in Japan in October 2008, in the United States in February 2012 and in China in July 2015At present, the domestic competition has the bemiprosin eye drops, qufu proprosin eye drops and latta prosin eye dropsDue to the non-medicy varieties compared with the price of high competition and other reasons, he fluoroproproszolin eye drops in the domestic market for many years sales are more dismalAccording to minet data, sales of hefluproproprosin at the end of China's public medical institutions in 2019 were 10.91 million yuan, up 49.04 percent year-on-yearChina's public medical institutions terminal hefluproproprotoxin sales (unit: million yuan)November 2019 he fluoroproproszolin eye drops were included in the national health insurance negotiation sequin, the cost of medical insurance payment is 74.8 yuan (2.5 ml: 37.5 ?g / branch), a decrease of 72.3%, the future sale of this product is expected to enter a rapid release periodAt present, the domestic market no generic drugs listed, Hengrui Pharmaceuticals he fluoroproproprosline listing application was included in the priority review, won the first imitation of the schedule will be greatly acceleratedIt is noteworthy that this is the re-emergence of Hengrui Pharmaceuticals in the field of ophthalmology, after the company announced that it will introduce the German Novaliq two dry eye drugs CyclASol (0.1% cyclosporine A preparation) and NOV03 (perfluorohexane), the expected total payment of more than 160 million U.Sdollars, Hengrui will receive the two new drugs in China, including clinical development, production and marketing rightsAs a domestic head pharmaceutical enterprises, in the face of the national collection to the industry brought pain, Hengrui Pharmaceuticals announced in 2019: cut a large number of generic drugs projects, only to do innovative drugs and high-end generic drugs with core valuesFrom the introduction of new drugs for dry eye disease into the ophthalmology drug market, to the pre-declaration of his fluoroproprosdontin generic drugs, Hengrui is undoubtedly fancy the potential of ophthalmic drugs trackTen billion ophthalmic drug market, TOP10 product exposure
China is not only the world's largest nearsighted country, but also one of the highest incidence of myopiaDue to the aging of the population, the widespread use of electronic products, improper use of the eye and other factors, dry eye disease, glaucoma, conjunctivitis, cataracts, age macular degeneration and other eyediseasesincreased significantlyWith the attention and attention paid to the prevention and effective treatment of ophthalmic diseases, the demand for ophthalmic drugs will continue to growIn 2019, sales of end-of-eye medicines in China's urban publichospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) amounted to 10.931 billion yuan, up 14.83 percent year-on-year, according to InternetAs can be seen, the domestic ophthalmic drug market is continuing to grow China's public medical institutions end-eye drug sales (units: 10,000 yuan) ophthalmic drug use pattern, eye vascular lesions treatment drugs, anti-infective drugs, anti-inflammatory drugs accounted for the majority of the market, accounting for 24.59 percent, 17.82, 9.56 percent, a total of 51.97 percent Ophthalmology agents mainly have eye preparations, injections, gels, tablets, capsules, eye preparations accounted for 63.29% of the market share, injections accounted for 29.88% 　　Ophthalmology drug productS TOP10, 10 products have sales of more than 100 million, 3 for exclusive products Thunderball single anti-injection, sodium heglass acid eye drops, Compaxip eye injection sales are more than 1 billion yuan The growth rate of sales of tammycin disemi eye drops continued to decline, with Kanghong Pharmaceuticals' new class 1 drug, Compaxip Eye Injection, leading the way with a growth rate of 32.56 percent 　　In 2019, China's public medical institutions terminal ophthalmic drug products TOP10 eye medicine drugs brand TOP10, Novartis, Ginseng Pharmaceuticals, URSAPHARM and other foreign brands occupy the majority of seats Novartis's Thunderball single anti-injection liquid with 1,246 million yuan sales ranked first, Ginseng Pharmaceutical's left oxyfluora star eye drops, sodium glass acid eye drops are on the list 　　2019 China's public medical institutions terminal ophthalmic drug brand TOP10
2020 to date approved eye medicine
2020 to date approved eye medicine 2020 to date, a total of 5 eye drug products in the domestic market approved for the market Yangzijiang Pharmaceutical Group, Zhongshan Wanhan Pharmaceutical's left-oxygen fluorosha star eye drops, The Coonbe subsidiary cherishming Ming pharmaceutical sodium glass acid eye drops, Chengdu Push Pharmaceutical sodium chloride eye drops are approved according to the newly registered classification of production, as if through a consistent evaluation 　　Minet consistency evaluation database shows that up to now ophthalmology drugs have sodium glass acid eye drops, hydrochloric acid Ollota drop eye drops, left oxyfluora star eye drops, sodium chloride eye drops and other 4 varieties (6 products) over-evaluation, are according to the newly registered classification batch production over-evaluation of the product of ophthalmic drugs
Chengdu Push Pharmaceuticals sodium glass acid eye drops, sodium chloride eye drops are the first evaluation In 2019, sales of sodium glass acid eye drops at the end of China's public medical institutions amounted to 1,211 million yuan, up 10.46 percent year-on-year, according to Minet Among them, The Company accounted for 43.45% of the market share, URSAPHARM accounted for 40.24% and Federal Pharmaceuticals 6.78% Push Pharmaceuticals, cherish Ming Pharmaceutical son joined, has the sodium glass acid eye drops to produce approval of the domestic pharmaceutical enterprises up to 16 　　China's public medical institutions terminal sodium glass acid eye drops sales (unit: million yuan) Yangzijiang Pharmaceutical Group's left oxygen fluorosa star eye drops for the first evaluation Minet data show that in 2019 China's public medical institutions terminal left oxyfluoroxastar eye drops sales of 750 million yuan, up 20.27 percent year-on-year, Ginseng Pharmaceuticals accounted for 88.97 percent of the market share, domestic replacement space is huge It is worth mentioning that the left oxygen fluoxastar eye drops for Yangzijiang Pharmaceutical Group's second ophthalmic drug products, the company in 2019 to harvest the first ophthalmic drug sodium glass acid eye drops 　　Xingqi eye medicine, popular in the capital market, after 2019 hydrochloric acid Ollota drop eye fluid, lysozyme drop eye fluid has been approved for production, 2020 so far no new products have been approved Minet data show that Xingqi eye medicine's cyclosporine eye drops (II), left oxyfluoroxastar eye drops, hydrochloric acid moxisastar eye drops, sodium glass acid eye drops, bemiprosin eye drops and other 5 products submitted according to the newly registered classification of the listing application in the review, once approved will be treated as a consistent evaluation In addition, the company's new class 2.4 class of atorasin sulfate eye drops have been advanced to clinical phase III Xingqi eye medicine in the review of the eye medication source: Mi net database note: statistics if there is a mistake, welcome to point the right!